These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21310613)

  • 21. Novel targets in solid tumors: MEK inhibitors.
    Messersmith WA; Hidalgo M; Carducci M; Eckhardt SG
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):831-6. PubMed ID: 17143253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.
    Li R; Xue L; Zhu T; Jiang Q; Cui X; Yan Z; McGee D; Wang J; Gantla VR; Pickens JC; McGrath D; Chucholowski A; Morris SW; Webb TR
    J Med Chem; 2006 Feb; 49(3):1006-15. PubMed ID: 16451066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma.
    Liu Y; Cai P; Wang N; Zhang Q; Chen F; Shi L; Zhang Y; Wang L; Hu L
    Biochem Biophys Res Commun; 2017 Mar; 484(2):378-384. PubMed ID: 28132803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.
    Aronov AM; Baker C; Bemis GW; Cao J; Chen G; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Martinez-Botella G; Namchuk MN; Straub J; Tang Q; Xie X
    J Med Chem; 2007 Mar; 50(6):1280-7. PubMed ID: 17300186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cascade approach to cyclic aminonitrones: reaction discovery, mechanism, and scope.
    Sharma R; Bulger PG; McNevin M; Dormer PG; Ball RG; Streckfuss E; Cuff JF; Yin J; Chen CY
    Org Lett; 2009 Aug; 11(15):3194-7. PubMed ID: 19572567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
    Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
    J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
    Ho MY; Morris MJ; Pirhalla JL; Bauman JW; Pendry CB; Orford KW; Morrison RA; Cox DS
    Xenobiotica; 2014 Apr; 44(4):352-68. PubMed ID: 23971497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a selective irreversible BMX inhibitor for prostate cancer.
    Liu F; Zhang X; Weisberg E; Chen S; Hur W; Wu H; Zhao Z; Wang W; Mao M; Cai C; Simon NI; Sanda T; Wang J; Look AT; Griffin JD; Balk SP; Liu Q; Gray NS
    ACS Chem Biol; 2013 Jul; 8(7):1423-8. PubMed ID: 23594111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.
    Hornberger KR; Chen X; Crew AP; Kleinberg A; Ma L; Mulvihill MJ; Wang J; Wilde VL; Albertella M; Bittner M; Cooke A; Kadhim S; Kahler J; Maresca P; May E; Meyn P; Romashko D; Tokar B; Turton R
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4511-6. PubMed ID: 23856049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
    Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C
    J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
    J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-
    Kurasawa O; Miyazaki T; Homma M; Oguro Y; Imada T; Uchiyama N; Iwai K; Yamamoto Y; Ohori M; Hara H; Sugimoto H; Iwata K; Skene R; Hoffman I; Ohashi A; Nomura T; Cho N
    J Med Chem; 2020 Feb; 63(3):1084-1104. PubMed ID: 31895562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The design and synthesis of 9-phenylcyclohepta[d]pyrimidine-2,4-dione derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase.
    Wang X; Lou Q; Guo Y; Xu Y; Zhang Z; Liu J
    Org Biomol Chem; 2006 Sep; 4(17):3252-8. PubMed ID: 17036113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging MEK inhibitors.
    McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):203-23. PubMed ID: 20151845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.